LeMaitre Vascular saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 74.
When To Sell Stocks To Lock In Profits And Minimize Losses
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if LeMaitre Vascular can continue to show renewed price strength and hit that benchmark.
LeMaitre Vascular is trying to complete a consolidation with a 109.58 entry. See if the stock can break out in volume at least 40% higher than normal.
LeMaitre Vascular showed 29% earnings growth in the latest quarterly report. Revenue rose 14%. Look for the next report on or around May 1.
The company holds the No. 12 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
